-
公开(公告)号:AU1067195A
公开(公告)日:1995-06-19
申请号:AU1067195
申请日:1994-11-26
Applicant: BASF AG
Inventor: STEINER GERD , MUNSCHAUER RAINER , UNGER LILIANE , TESCHENDORF HANS-JURGEN , HOGER THOMAS
IPC: C07D401/04 , A61K31/40 , A61K31/403 , A61K31/44 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/505 , A61P25/00 , A61P25/02 , A61P25/08 , A61P25/18 , A61P25/28 , A61P43/00 , C07D209/02 , C07D209/46 , C07D209/52 , C07D209/90 , C07D209/96 , C07D403/04 , C07D403/06 , C07D405/06 , C07D409/04 , C07D409/06 , C07D413/06 , C07D409/14
Abstract: PCT No. PCT/EP94/03910 Sec. 371 Date Apr. 19, 1996 Sec. 102(e) Date Apr. 19, 1996 PCT Filed Nov. 26, 1994 PCT Pub. No. WO95/15312 PCT Pub. Date Jun. 8, 1995Compounds of the formula I I where the substituents have the meanings given in the description, and their preparation are described. The novel compounds are suitable for the control of diseases.
-
公开(公告)号:CA2330206C
公开(公告)日:2010-04-13
申请号:CA2330206
申请日:1999-06-04
Applicant: BASF AG
Inventor: KOCK MICHAEL , HOGER THOMAS , KROGER BURKHARD , OTTERBACH BERND , LUBISCH WILFRIED , LEMAIRE HANS-GEORG
IPC: A01K67/027 , C12N15/54 , A61K31/70 , A61K38/00 , A61K38/45 , A61K39/395 , A61K48/00 , A61K49/00 , A61P43/00 , C07K14/455 , C07K16/40 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/10 , C12N15/09 , C12N15/10 , C12N15/63 , C12Q1/48 , C12Q1/68 , G01N33/53 , G01N33/566
Abstract: The invention relates to poly(ADP-ribose)polymerase (PARP) homologues which are characterised by an amino acid sequence with a) a functional NAD+ -binding site and b) no zinc-finger-sequence motif of general formula CX2CX m HX2C, wherein m is an integral number 28 or 30 and the radicals X represent any amino acid, independently of each other, and to the functional equivalents of said poly(ADP-ribose)polymerase (PARP) homologues. The invention also relates to nucleic acids coding the poly(ADP-ribose)polymerase (PARP) homologues, to antibodies with specificity for the novel protein, to pharmaceutical and gene therapy agents containing the inventive products, to methods for analytically determining the inventive proteins and nucleic acids, to methods for identifying the effectors or bonding partners of the inventive proteins, to novel PARP effectors and to methods for determining the effectiveness of effectors of this type.
-
公开(公告)号:AU765224B2
公开(公告)日:2003-09-11
申请号:AU1266500
申请日:1999-10-28
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS
IPC: G01N33/53 , A61K31/00 , A61K31/4184 , A61K31/4427 , A61K31/454 , A61K31/496 , A61K31/55 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P13/12 , A61P25/08 , A61P25/10 , A61P25/28 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C237/30 , C07D235/18 , C07D401/10 , C07D403/10 , C07D521/00 , C12Q1/48 , G01N33/00 , G01N33/15 , G01N33/573 , G01N33/577
Abstract: 2-Phenyl-benzimidazolecarboxamide derivatives (I) and (II) are new. 2-Phenyl-benzimidazolecarboxamide derivatives of formulae (I) and (II) and their tautomers, enantiomers, diastereomers, prodrugs and salts, are new: [Image] R 1>H or alkyl optionally substituted with OH, alkoxy, amino (optionally mono- or disubstituted) or optionally substituted piperidino, piperazino, pyrrolidino, hexahydroazepino, morpholino or 4,5-dihydropyridino; R 2>H, Cl, Br, I, F, CF 3, NO 2, NHCOR 2> 1>, NR 2> 2>R 2> 3>, OH, alkoxy, alkoxy-Ph, NH 2, or Ph; R 2> 1>, R 2> 2>alkyl; R 2> 3>H, alkyl, or optionally substituted phenyl; x : 0-2; R 3>D-(F 1>) p-(E) q-(F 2>) r-G, E-(D) u-(F 2>) s-(G) v or B; R 4>H, Cl, F, Br, I, alkyl, OH, NO 2, CF 3, CN, NR 4> 4>R 4> 2>, NHCOR 4> 3>, or alkoxy; R 4> 1>, R 4> 2>H or alkyl; R 4> 3>H, alkyl, alkyl-phenyl, or phenyl; D : O or S; E : phenyl, imidazole, pyrrole, thiophene, pyridine, pyrimidine, piperazine, pyrazine, furan, thiazole, isoxazole, pyrrolidine, piperidine or optionally substituted trihydroazepine ring; F 1>, F 2>1-8C chain optionally substituted with OH or alkoxy; p-v : 0 or 1, but p, q and r are not simultaneously 0; G : NR 5> 1>R 52>or optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; R 5> 1>alkyl or (CH 2) t-K; B : optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; t : 0-4; K : optionally substituted phenyl, NR 4> 1>R 4> 2>, phenyl-alkyl-NH, pyrrolidino, piperidino, 1,2,5,6-tetrahydropyridino, morpholino, trihydroazepino, or piperazino or homopiperazino (both optionally substituted with alkyl); R 5>H, alkyl, NR 7>R 9>, or optionally substituted pyrrolidinyl, piperidinyl, 1,2,5,6-tetrahydropyridyl, piperizinyl, azepinyl, morpholinyl or 1,4-diazepanyl; The full definitions are given in the DEFINITIONS (Full Definitions) Field. Independent claims are also included for the following: (i) aminobenzamide intermediates of formulae (III) and (IV) and their salts; (ii) preparation of compounds (III) and (IV); (iii) an in vitro method for the detection of poly(ADP-ribose)polymerase (PARP) inhibitors comprising: (a) incubating a poly-ADP-ribosylable target (optionally bonded to a carrier) with a reaction mixture comprising a PARP, a PARP activator and a PARP inhibitor or an analyte in which one or more PARP inhibitors is presumed to exist; (b) carrying out a poly-ADP-ribosylation reaction; and (c) qualitatively or quantitatively determining the poly-ADP-ribosylation with an anti-poly-(ADP-ribose) antibody. [Image] ACTIVITY : None given. MECHANISM OF ACTION : Poly(ADP-ribose)polymerase (PARP) inhibitor.
-
公开(公告)号:NZ511825A
公开(公告)日:2003-08-29
申请号:NZ51182599
申请日:1999-11-23
Applicant: BASF AG
Inventor: KOCK MICHAEL , HOGER THOMAS , SCHULT SABINE , GRANDEL ROLAND , MULLER REINHOLD , LUBISCH WILFRIED
IPC: A61K20060101 , A61K31/4184 , A61K31/454 , A61K31/496 , A61P20060101 , A61P3/12 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/02 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P43/00 , C07D20060101 , C07D235/30 , C07D401/04 , C07D401/14 , C07D403/04 , A61P3/10 , A61K31/551 , A61K31/4545
Abstract: Compounds of general formula (Ia) or (Ib) wherein R-1 and R4 are hydrogen or defined substituents, A is a saturated or monoethenoid heterocyclic ring with 4 to 8 members which contains one or two nitrogen atoms, wherein additionally one oxygen or sulfur atom can be present. Said ring can be further substituted. The invention also relates to their tautomer forms, possible enantiomer and diastereomer forms, their prodrugs, as well as possible physiologically acceptable salts. The invention also relates to the use of said compounds for treating diseases related to a pathologically increased activity of PARP.
-
公开(公告)号:SK3802002A3
公开(公告)日:2003-03-04
申请号:SK3802002
申请日:2000-09-15
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS , GRANDEL ROLAND , MULLER REINHOLD , SCHULT SABINE
-
86.
公开(公告)号:CZ20013775A3
公开(公告)日:2002-10-16
申请号:CZ20013775
申请日:2000-04-11
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS , GRANDEL ROLAND , SCHULT SABINE , MULLER REINHOLD
IPC: C07D235/08 , A61K31/4184 , A61K31/4427 , A61K31/4523 , A61K31/496 , A61K31/551 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P43/00 , C07D235/10 , C07D235/12 , C07D235/14 , C07D235/16 , C07D401/08 , C07D403/08 , C07D235/06
Abstract: Compounds of the formula I or IIand their tautomeric forms, possible enantiomeric and diastereomeric forms, possible cistrans isomers on the rings in A and prodrugs thereof, pharmaceutical compositions containing these compounds and methods of treating neurodegenerative diseases or neuronal damage with these compounds.
-
公开(公告)号:CO5170500A1
公开(公告)日:2002-06-27
申请号:CO00028650
申请日:2000-04-18
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS , GRANDEL ROLAND , SCHULT SABINE , MULLER REINHOLD
IPC: C07D235/08 , A61K31/165 , A61K31/415 , A61K31/4184 , A61K31/4427 , A61K31/4523 , A61K31/496 , A61K31/551 , A61P3/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P43/00 , C07D235/10 , C07D235/12 , C07D235/14 , C07D235/16 , C07D401/08 , C07D403/08
Abstract: Compuestos de las fórmulas I ó II: dondeA significa un carbociclo saturado o monoinsaturado con 3 a 8 átomos de carbono, que pueden tener adicionalmente un anillo benceno condensado, cuyos anillos pueden estar sustituidos adicionalmente por uno o dos radicales R3 idénticos o diferentes, así como el radical R4, yR1 hidrógeno, cloro, fluoro, bromo, yodo, C1-C6-alquilo ramificado y sin ramificar, OH, nitro, CF3, CN, NR11R12, NH-CO-R13, O-C1-C4-alquilo, significando R11 y R12, cada uno independientemente del otro, hidrógeno o C1-C4-alquilo yR13 hidrógeno, C1-C4-alquilo, C1-C4-alquil-fenilo o fenilo,YR2 significa hidrógeno, C1-C6-alquilo ramificado y sin ramificar, C1-C4-alquilo, fenilo yR3 significa C1-C6-alquilo, OH, O-C1-C4-alquilo, OC1-C4-alquil-fenilo, NR11R12, fenilo, C1-C4-alquil-fenilo, CF3, COOH, COOC1-C4-alquilo, CONH-C1-C4-alquilo, CONH2, pudiendo los anillos fenilo estar sustituidos aún por, como máximo, dos radicales R31 idénticos o diferentes, yR31 significa OH, C1-C6-alquilo, OC1-C4-alquilo, cloro, bromo, yodo, fluoro, CF3, nitro, NH2, y R4 significa -(O)p.(CH2)q-B, dondeB es NR41R42 SignificandoP 0 y 1 yq 0, 1, 2 ó 3, pudiendo, cuando q = 0 p también ser igual a 0, y- 2 -R41 significa hidrógeno, C1-C6-alquilo, (CH2)r-E yR42 significa hidrógeno, C1-C6-alquilo, -CO-R8, SO2-R8, -(C=N)-R8 y -(C=N)- NHR8 yr es 0,1,2,3,4 yE significa fenilo, que puede llevar aún, como máximo dos radicales R72, y, cuando r ? 0, 1, también NR11R12, NH-C1-C4-alquil-fenilo, pirrolidina, piperidina, dihidropiperidina, morfolina, homopiperidina, piperacina, que puede estar sustituída aún por C1-C6-alquilo y C1-C6-alquil-fenilo, y homopiperacina, que puede estar sustituída aún por C1-C6-alquilo y C1-C4-alquil-fenilo, yR7 significa hidrógeno, C1-C6-alquilo, fenilo, pudiendo el anillo estar sustituido aún por hasta dos radicales R71 idénticos o diferentes, yR71 significa OH, C1-C6-alquilo, O-C1-C4-alquilo, cloro, bromo, yodo, fluoro, CF3, nitro, NR11R12, yR72 significa OH, C1-C6-alquilo, O-C1-C4-alquilo, cloro, bromo, yodo, fluoro, CF3, nitro, NR11R12, yR8 significa C1-C6-alquilo, fenilo, C1-C4-alquil-fenilo, pudiendo el anillo estar sustituído aún por hasta dos radicales R81 idénticos o diferentes, yR81 significa OH, C1-C6-alquilo, O-C1-C4-alquilo, cloro, bromo, yodo, fluoro, CF3, nitro, NR11R12, yR9 significa hidrógeno, C1-C6-alquilo, C1-C4-alquil-fenilo, fenilo, pudiendo el anillo estar sustituido aún por hasta dos radicales R91 idénticos o diferentes, y R91 significa OH, C1-C6-alquilo, O-C1-C4-alquilo, cloro, bromo, yodo, fluoro, CF3, nitro NR11R12,así como sus formas tautómeras, sus formas enantiómeras y diastereómeras posibles, los isómeros cis.-trans en los anillos A y sus prodrogas.
-
公开(公告)号:CZ20014038A3
公开(公告)日:2002-06-12
申请号:CZ20014038
申请日:2000-05-03
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , SADOVSKI JENS , KOCK MICHAEL , HOGER THOMAS
IPC: C07D237/32 , A61K31/502 , A61P1/10 , A61P9/00 , A61P9/10 , A61P13/12 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/10 , A61P25/12 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P37/00 , A61P41/00 , A61P43/00 , C07D401/12 , C07D403/12
Abstract: The present invention relates to the use of phthalazine derivatives as inhibitors of the enzyme poly(ADP-ribose) polymerase or PARP (EC 2.4.2.30), to the use as inhibitors of PARP-homologous enzymes and, in particular, these phthalazine derivatives also show a selective inhibition of PARP-homologous enzymes.
-
公开(公告)号:CO5140115A1
公开(公告)日:2002-03-22
申请号:CO99072377
申请日:1999-11-17
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS
IPC: C07D235/18 , A61K20060101 , A61K31/10 , A61K31/395 , A61K31/404 , A61K31/41 , A61K31/4184 , A61K31/454 , A61P20060101 , A61P3/10 , A61P7/02 , A61P9/00 , A61P13/12 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/00 , A61P35/00 , A61P35/04 , A61P37/02 , A61P43/00 , C07D20060101 , C07D209/14 , C07D235/04
Abstract: Uso de compuestos de la fórmula I En dondeA significa hidrógeno, alquilo C1-C4 ramificado y no ramificado pudiendo un átomo C del resto alquilo llevar OR11 o un grupo R5, en dondeR11 significa hidrógeno o alquilo C1-C4, yR2 significa hidrógeno, cloro, flúor, bromo, yodo, alquilo C1-C6 ramificado y no ramificado, nitro, CF3, CN, NR21R22, NH-COR23, OR21, en donde R21 y R22 independientemente uno de otro significan hidrógeno o alquilo C1-C4, yR23 significa hidrógeno, alquilo C1-C4 o fenilo, yR3 significa -(CH2)q-NR31R32, (CH2)q-NR33R34, en donde q puede ser 0, 1, 2 o 3, R31 significa hidrógeno, alquilo C1-C6, (CH2)r-NR33R34R32 significa (CH2)r-NR33R34 en donde R31 y R32, independientemente uno de otro, rSignifica 2, 3, 4, 5 o 6 y R33 y R34 independientemente uno de otro son iguales a hidrógeno, alquilo C1-C6, junto con el nitrógeno iguales a un anillo de 3 a 8 átomos, que puede llevar un heteroátomo adicional seleccionado entre 0, N-C1-C4-alquilo, N-Co-C2-fenilo o NH, fenilo-C1-C4-alquilo, en donde el anillo fenilo puede tener hasta 3 sustituyentes iguales o diferentes seleccionados entre el grupo alquilo C1-C6, halógeno, nitro, S02NR35R36 (con R35, R36 independientemente uno de otro iguales a hidrógeno, alquilo C1-C4 o junto con el nitrógeno iguales a un anillo de 3 a 8 átomos, que puede llevar un heteroátomo adicional seleccionado entre O, S, SO2, N-C1-C4-alquilo, N-Co-C2-fenilo o NH), alcoxi C1-C4, S(O)o-2-R37 (con R37 igual a hidrógeno, alquilo C1-C4), CF3, (CH2)o-4-COR37, (CH2)o-4-NR35R36, (CH2)0-4-CONR35R36, (CH2)o-4-0R37-CH2COOR37,R4 significa hidrógeno, alquilo C1-C6 ramificado y no ramificado, cloro, bromo, flúor, nitro, ciano, NR41R42, NH-CO-R43, OR41, en dondeR41 y R42 independientemente uno de otro significan hidrógeno o alquilo C1-C4 yR43 significa alquilo C1-C4 o fenilo,así como también sus formas tautómeras, posibles formas enantiómeras y diastereómeras, sus prodrogas, así como también posibles sales fisiológicamente compatibles, para la preparación de medicamentos para el tratamiento de enfermedades en las cuales aparece una actividad patológicamente aumentada de PARP.
-
公开(公告)号:SK8842001A3
公开(公告)日:2002-01-07
申请号:SK8842001
申请日:2000-09-15
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , KOCK MICHAEL , HOGER THOMAS , SCHULT SABINE , GRANDEL ROLAND , MULLER REINHOLD
IPC: A61K31/55 , A61P3/10 , A61P9/10 , A61P11/00 , A61P13/12 , A61P19/02 , A61P25/00 , A61P25/08 , A61P25/10 , A61P25/14 , A61P25/16 , A61P25/28 , A61P29/00 , A61P35/00 , C07D487/06
Abstract: The invention relates to compounds of formula (I) as well as to the tautomeric forms thereof, possible enantiomeric and diastereomeric forms and the prodrugs thereof, the production and use thereof, whereby the values have the meaning as given in the description.
-
-
-
-
-
-
-
-
-